Faculty who have authored publication Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Name | Title | Department | Institution |
---|---|---|---|
Razelle Kurzrock MD | Center Associate Director, Professor | Medicine | Medical College of Wisconsin |